Cypress Funds’s Alexion Pharmaceuticals ALXN Stock Holding History

Cypress Funds’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-50,000	Closed	-$6.06M	–	31
2017 Q1	$6.06M	Hold	50,000	–	–	1.26%	24
2016 Q4	$6.12M	Buy	+50,000	New	+$6.12M	1.03%	25

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cypress Funds's ALXN Position: Q2 2017 in Review

Cypress Funds sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 222,000 shares — an estimated $26.9M sold.

Cypress Funds first reported a position in ALXN in Q3 2016 and held it in 3 quarters. The position peaked at $26.9M in Q1 2017. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

Cypress Funds reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Cypress Funds sold 222,000 Alexion Pharmaceuticals shares in Q2 2017, an estimated $26.9M.
Cypress Funds first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 3 quarters.
Cypress Funds's Alexion Pharmaceuticals position peaked at $26.9M in Q1 2017.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Cypress Funds's 13F filing for Q2 2017, filed 25 Jul 2017.